Transgenomic, Inc. (OTCBB: TBIO) today announced that it has been awarded the 2013 Governor’s Bioscience Award. Gov. Dave Heineman presented the award Tuesday to Transgenomic President and CEO Craig Tuttle at the Bio Nebraska Life Sciences Association annual meeting, held at the Gallup Corporation's Omaha campus.

From left: Nebraska Governor Dave Heineman, Craig Tuttle, President and Chief Executive Officer of Transgenomic, and Phil Kozera, Executive Director, Bio Nebraska Life Sciences Association. (Photo: Bio Nebraska Life Sciences Association)

"Transgenomic is an example of the life science gems we have in our state," Gov. Heineman said. "This company is the global leader in cardiac genetic testing with a family of innovative products. We are pleased to be able to recognize them for their achievements in biotechnology and their contributions to the growth of healthcare and the life sciences in Nebraska."

“We are honored to be recognized with this notable award,” said Craig Tuttle, Chief Executive Officer of Transgenomic. “We sincerely thank Bio Nebraska and Governor Heineman for the opportunity this award brings, and for the attention it garners from the larger life sciences community.”

The bioscience award, created by Nebraska artist and Hastings College art professor Tom Kreager, recognizes individuals and companies that have made significant contributions to the bioscience industry in Nebraska.

About Bio Nebraska

The mission of Bio Nebraska is to be the champion of biotechnology and to advocate for its member organizations, promoting academic, industry and government partnerships to foster the growth of life sciences within Nebraska. Nebraska biotechnology researchers expand the boundaries of science to benefit mankind by providing better health care, enhanced agriculture and a cleaner and safer environment, creating opportunities for economic development within the state.

About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is a global leader in cardiac genetic testing with a family of innovative products, including its C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Telesis Bio (PK) (USOTC:TBIO)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Telesis Bio (PK)
Telesis Bio (PK) (USOTC:TBIO)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Telesis Bio (PK)